Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole Inhalation Powder in Asthma
NCT04576325Phase 1Completed
- Sponsor
- TFF Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of voriconazole in Invasive Pulmonary Aspergillosis (IPA) and allergic bronchopulmonary aspergillosis (ABPA) (4 arms), sponsored by TFF Pharmaceuticals. Primary endpoints: Adverse Events, Serious Adverse Events and withdrawals due to AEs, Vital sign abnormalities and 4 more. Started Nov 2020; status: completed.
02
Drugs
voriconazole
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT04576325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576325.